725 related articles for article (PubMed ID: 16204009)
21. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.
Bollard CM; Gottschalk S; Torrano V; Diouf O; Ku S; Hazrat Y; Carrum G; Ramos C; Fayad L; Shpall EJ; Pro B; Liu H; Wu MF; Lee D; Sheehan AM; Zu Y; Gee AP; Brenner MK; Heslop HE; Rooney CM
J Clin Oncol; 2014 Mar; 32(8):798-808. PubMed ID: 24344220
[TBL] [Abstract][Full Text] [Related]
22. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma.
Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX
Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
Liu MT; Yeh CY
Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
[TBL] [Abstract][Full Text] [Related]
24. Functional assays of HLA A2-restricted epitope variant of latent membrane protein 1 (LMP-1) of Epstein-Barr virus in nasopharyngeal carcinoma of Southern China and Taiwan.
Lin HJ; Cherng JM; Hung MS; Sayion Y; Lin JC
J Biomed Sci; 2005 Dec; 12(6):925-36. PubMed ID: 16307312
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
26. Establishment of cytotoxic T lymphocytes specific for autologous Epstein-Barr virus in HIV-infected patients: the feasibility study of EBV-specific immunotherapy for patients with EBV-associated lymphoma.
Hansasuta P; Incomserb P; Buranapraditkun S; Bhattarakosol P
J Med Assoc Thai; 2004 Sep; 87 Suppl 2():S146-51. PubMed ID: 16083179
[TBL] [Abstract][Full Text] [Related]
27. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy.
Sherritt MA; Bharadwaj M; Burrows JM; Morrison LE; Elliott SL; Davis JE; Kear LM; Slaughter RE; Bell SC; Galbraith AJ; Khanna R; Moss DJ
Transplantation; 2003 May; 75(9):1556-60. PubMed ID: 12792514
[TBL] [Abstract][Full Text] [Related]
28. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells.
Lee SP; Chan AT; Cheung ST; Thomas WA; CroomCarter D; Dawson CW; Tsai CH; Leung SF; Johnson PJ; Huang DP
J Immunol; 2000 Jul; 165(1):573-82. PubMed ID: 10861098
[TBL] [Abstract][Full Text] [Related]
29. Establishment and characterization of Epstein-Barr virus-specific human CD4+ T lymphocyte clones.
Honda S; Takasaki T; Okuno K; Yasutomi M; Kurane I
Acta Virol; 1998 Nov; 42(5):307-13. PubMed ID: 10358731
[TBL] [Abstract][Full Text] [Related]
30. [Sequence analysis of the CTL epitopes in transmembrane region of latent membrane protein 2 of Epstein-Barr virus derived from nasopharyngeal carcinoma cells].
Zhang NH; Zhang XS; Li J; Zhang RH; Gao YF; Zeng MS
Ai Zheng; 2006 May; 25(5):566-9. PubMed ID: 16687075
[TBL] [Abstract][Full Text] [Related]
31. Conjugation of latent membrane protein (LMP)-2 epitope to gold nanoparticles as highly immunogenic multiple antigenic peptides for induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses in vitro.
Cheung WH; Chan VS; Pang HW; Wong MK; Guo ZH; Tam PK; Che CM; Lin CL; Yu WY
Bioconjug Chem; 2009 Jan; 20(1):24-31. PubMed ID: 19102689
[TBL] [Abstract][Full Text] [Related]
32. Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant.
Regn S; Raffegerst S; Chen X; Schendel D; Kolb HJ; Roskrow M
Bone Marrow Transplant; 2001 Jan; 27(1):53-64. PubMed ID: 11244438
[TBL] [Abstract][Full Text] [Related]
33. Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma.
Paramita DK; Fachiroh J; Artama WT; van Benthem E; Haryana SM; Middeldorp JM
J Med Virol; 2007 Nov; 79(11):1710-21. PubMed ID: 17854043
[TBL] [Abstract][Full Text] [Related]
34. Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15.
Wagner HJ; Sili U; Gahn B; Vigouroux S; Huls MH; Xie W; Vignali D; Brenner MK; Heslop HE; Rooney CM
Cytotherapy; 2003; 5(3):231-40. PubMed ID: 12850791
[TBL] [Abstract][Full Text] [Related]
35. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
[TBL] [Abstract][Full Text] [Related]
36. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease.
Lucas KG; Salzman D; Garcia A; Sun Q
Cancer; 2004 May; 100(9):1892-901. PubMed ID: 15112270
[TBL] [Abstract][Full Text] [Related]
37. Induction of T-cell immunity against Epstein-Barr virus-associated tumors by means of adenovirally transduced dendritic cells.
Sun H; Yao K; Chen Y; Zhou F
Chin Med J (Engl); 2004 Oct; 117(10):1558-63. PubMed ID: 15498383
[TBL] [Abstract][Full Text] [Related]
38. Serum responses to the combination of Epstein-Barr virus antigens from both latent and acute phases in nasopharyngeal carcinoma: complementary test of EBNA-1 with EA-D.
Chow KC; Ma J; Lin LS; Chi KH; Yen SH; Liu SM; Liu WT; Chen WK; Chang TH; Chen KY
Cancer Epidemiol Biomarkers Prev; 1997 May; 6(5):363-8. PubMed ID: 9149897
[TBL] [Abstract][Full Text] [Related]
39. T cell repertoire and Epstein-Barr virus-specific T cell response in chronic active Epstein-Barr virus infection: a case study.
Gallot G; Hamidou MA; Clémenceau B; Gaschet J; Tiberghien P; Ferrand C; Vivien R; Barbarot S; Coste-Burel M; Moreau A; Vié H
Clin Immunol; 2006 Apr; 119(1):79-86. PubMed ID: 16386957
[TBL] [Abstract][Full Text] [Related]
40. Alteration of cellular mediated cytotoxicity, T cell receptor zeta (TcR zeta) and apoptosis related gene expression in nasopharyngeal carcinoma (NPC) patients: possible clinical relevance.
Laytragoon-Lewin N; Porwit-MacDonald A; Mellstedt H; Lewin F
Anticancer Res; 2000; 20(2B):1093-100. PubMed ID: 10810402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
